• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data nears

cafead

Administrator
Staff member
  • cafead   Sep 17, 2023 at 09:33: PM
via Lyndra Therapeutics is laying off roughly 23% of its staff, two months after the company swapped out longtime CEO Patricia Hurter, Ph.D., and as a pivotal trial for a long-acting, oral schizophrenia drug nears an interim readout.

article source
 

<